Test glutathione for brain inflammation in Alzheimer’s
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This early-stage study tests whether taking glutathione can affect brain “inflammation” and metabolism in people with Alzheimer’s disease. You might benefit from a new treatment approach, while helping researchers understand what works best for early Alzheimer’s-related brain changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 85 years old
- Your memory problems have been slowly getting worse for over 1 year
- Your memory testing score is between 10 and 20 on the Montreal Cognitive Assessment (MoCA)
- A PET brain scan shows amyloid deposits (amyloid-positive)
- You can bring a study partner who will be involved with study visits
- You have not been hospitalized in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This trial tests whether a gentle, non-invasive brain stimulation (transcranial alternating current) can improve memory and thinking in people with early Alzheimer's or mild memory problems. It involves regular sessions of stimulation and check-ups over several months.
This trial studies whether treating periodontal (gum) disease can help people who have probable Alzheimer’s disease. You may take a study treatment and have regular checks by a caregiver and study team.
This study tests whether a supplement called gamma-glutamylcysteine can increase levels of a natural antioxidant called glutathione in the brain of people with Parkinson's. If you are between 50 and 80 and have mild cognitive symptoms, this trial may help researchers understand a new way to support brain health.
This Phase 1 study tests whether stimulating the immune system (through a receptor called TLR9) is safe and may affect brain changes in people with early Alzheimer’s. It mainly enrolls older adults with memory impairment confirmed by specific amyloid imaging.
This study tests whether a natural substance called NAD can improve brain health in people with early Alzheimer's. You may be eligible if you have a firm Alzheimer's diagnosis, are between 65 and 80, and can walk and talk without help.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.